Observational study · people

Melanotan I: heavy EPP life impact fell from 75% to 0% of patients

Checked against the paper Observational studyPublished by PepVault

The takeaway

Patients with EPP on afamelanotide reported their disease weighed on their lives far less after treatment, and more of them went outside, though this comes from an uncontrolled survey.

Kind
Observational study
Studied in
People
Published
2023
Journal
J Drugs Dermatol

What they tested

The team wanted to know how patients with erythropoietic protoporphyria (EPP), a rare disease that makes skin painfully sensitive to light, rated the benefit of afamelanotide treatment.

How the study was done

An observational questionnaire study of US patients with EPP receiving afamelanotide implants. Patients rated things like getting back to normal activities, light-triggered skin reactions and confidence on a scale running from very much to never.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Melanotan I? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Before treatment, 75% of patients said EPP affected their lives very much or a lot. After the first implant that share dropped to 11%, and after each later implant it was 0%. The number of patients who chose to go outside rose with each new implant.

What it doesn’t show

This was a self-rated patient survey with no comparison group, so it can't separate the drug's effect from other factors or from patients' expectations. It measured how patients felt about their lives, not lab or clinical measures of light sensitivity.

The paper

Resnik et al. Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States. J Drugs Dermatol. 2023.

The compound

More studies on Melanotan I

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Melanotan I? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo